Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-28 | Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She has extensive medical and scientific expertise. |
| 2021-04-08 | Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. |
| 2022-04-07 | Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine |
| 2023-04-06 | Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020; holds a B.A. and an M.D. |
| 2024-04-04 | Dr. Kewalramani possesses strong leadership qualities, significant experience overseeing and scaling the operations of a global enterprise, deep expertise in drug development, and wide-ranging experience in policy matters, demonstrated through her services as a senior executive in the biotechnology sector. She is a physician-executive with extensive industry knowledge garnered through her scientific and medical roles and experience as a global senior leader across multiple disease areas and all stages of drug development. |
| 2025-04-03 | Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine; alumna of the Harvard Business School |
Data sourced from SEC filings. Last updated: 2025-08-30